1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

06 Nov 2025
Admin
News Article

FDA Approves Galderma’s Restylane Lyft with Lidocaine for Chin Augmentation

October 2025 — Texas, USA: Galderma announced that the U.S. Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocaine for chin augmentation in adults over 21 with mild-to-moderate chin retrusion. The decision expands the product’s existing approvals for midface contouring, facial folds, wrinkles, and hand rejuvenation.

Restylane Lyft, developed with NASHA technology, features a firmer hyaluronic acid (HA) gel designed to add structure and support. With its high G-prime value—a measure of firmness—the injectable aims to deliver enhanced chin projection and facial balance.

“This approval reinforces our commitment to advancing our Injectable Aesthetics portfolio to meet diverse patient needs,” said Bill Andriopoulos, Vice President of Medical Affairs, Galderma US.

Clinical Results Support Long-Term Efficacy

The FDA approval is based on a pivotal clinical trial assessing the safety and effectiveness of Restylane Lyft for chin enhancement.
Key findings include:

Primary endpoint met: Significant improvement in chin projection at three months, maintained through 12 months.
High satisfaction rates: At Month 3, 99.1% of investigators and 94.4% of subjects reported visible improvement; these figures remained above 89% at Month 12.
Natural-looking results: Up to 86.3% of patients agreed that the treatment delivered a balanced and natural chin-to-jawline transition.
Favourable safety profile: No serious or unexpected adverse events were reported.

“The chin plays a vital role in overall facial harmony,” said Dr. Alia S. Brown, cosmetic dermatologist at Georgia Dermatology Partners. “Restylane Lyft provides a safe and effective option to enhance facial balance.”

Global Expansion Plans

Galderma plans to submit regulatory applications for the new indication in additional markets worldwide. The company stated that it aims to make the chin augmentation indication available in as many countries as possible.

About Restylane

The Restylane portfolio includes a range of HA injectables designed to provide customized aesthetic outcomes. The products use advanced HA technologies—NASHA HD, NASHA, and OBT/XpresHAn—to replicate the skin’s natural structure while offering flexibility, support, and natural-looking results.

With over 20 years of global safety data, Restylane is among the most widely used injectable brands in aesthetic medicine.

About Galderma

Galderma is a leading dermatology company operating in about 90 countries. Its portfolio spans injectable aesthetics, dermatological skincare, and therapeutic dermatology, combining science-driven innovation with premium consumer and professional products.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!